From disease activity scores to precision medicine: biomarkers and composite models for risk stratification in chronic spontaneous urticaria.
- 1Allergy and Immunology Department, Medical Subspecialties Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
- 2Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom.
Abstract
Chronic spontaneous urticaria is a common, mast cell driven condition that presents with wheals, angioedema, or both, and a substantial proportion of patients remain inadequately controlled despite guideline-directed antihistamine therapy. The 2026 guideline has expanded the advanced-treatment options to include omalizumab, dupilumab and remibrutinib, while ciclosporin remains an alternative later-line immunosuppressive option, yet it is organised around treatment response rather than prognosis, so patients with difficult-to-control disease are often recognised only after months of sequential escalation. This narrative review examines the scoring systems and biomarkers available in urticaria and angioedema and considers whether they can support early risk stratification and help identify patients at increased risk of difficult-to-control disease. The validated instruments in routine use, namely the Urticaria Activity Score, the Urticaria Control Test, the Chronic Urticaria Quality of Life Questionnaire, and their angioedema counterparts, measure current disease activity, control, and quality of life rather than long term outcome. A separate body of work has described biomarkers associated with the autoimmune type IIb endotype and with response to omalizumab, including low total IgE, a high ratio of IgG anti-thyroid peroxidase to total IgE, basopenia, and raised inflammatory markers, although most of this evidence is associative rather than prospectively predictive. The distinction between markers of current burden, markers of prognosis, and markers of treatment response is emphasised. Composite models integrating clinical characteristics, patient-reported outcomes, and biomarkers represent a promising approach toward precision management of CSU, although no validated prognostic tool is currently available for routine clinical use.
Related
- Toward Precision Colorectal Cancer Screening: Integrating Clinical Risk Stratification, Molecular Biomarkers, and Artificial Intelligence
- Treatment Choice and Cardiovascular Risk in Chronic Spontaneous Urticaria.
- Lower Serum SCCA2 Detectability in Chronic Spontaneous Compared with Chronic Inducible Urticaria: A Prospective Observational Study
- Efficacy and safety of acupuncture therapy for chronic spontaneous urticaria: a network meta-analysis based on randomized controlled trials
- Comorbidities in Chronic Spontaneous Urticaria: Integrating Disease Drivers and Systemic Consequences
BibTeX
@article{elkhalifa2026from,
title = {{From disease activity scores to precision medicine: biomarkers and composite models for risk stratification in chronic spontaneous urticaria.}},
author = {Shuayb Elkhalifa and Mohamed Abuzakouk},
journal = {Frontiers in allergy},
year = {2026},
month = oct,
doi = {10.3389/falgy.2026.1962595},
url = {https://europepmc.org/article/MED/42922821},
note = {CC BY},
}
RIS
TY - JOUR
TI - From disease activity scores to precision medicine: biomarkers and composite models for risk stratification in chronic spontaneous urticaria.
AU - Shuayb Elkhalifa
AU - Mohamed Abuzakouk
PY - 2026
DA - 2026/10/08
JO - Frontiers in allergy
DO - 10.3389/falgy.2026.1962595
UR - https://europepmc.org/article/MED/42922821
AB - Chronic spontaneous urticaria is a common, mast cell driven condition that presents with wheals, angioedema, or both, and a substantial proportion of patients remain inadequately controlled despite guideline-directed antihistamine therapy. The 2026 guideline has expanded the advanced-treatment options to include omalizumab, dupilumab and remibrutinib, while ciclosporin remains an alternative later-line immunosuppressive option, yet it is organised around treatment response rather than prognosis, so patients with difficult-to-control disease are often recognised only after months of sequential escalation. This narrative review examines the scoring systems and biomarkers available in urticaria and angioedema and considers whether they can support early risk stratification and help identify patients at increased risk of difficult-to-control disease. The validated instruments in routine use, namely the Urticaria Activity Score, the Urticaria Control Test, the Chronic Urticaria Quality of Life Questionnaire, and their angioedema counterparts, measure current disease activity, control, and quality of life rather than long term outcome. A separate body of work has described biomarkers associated with the autoimmune type IIb endotype and with response to omalizumab, including low total IgE, a high ratio of IgG anti-thyroid peroxidase to total IgE, basopenia, and raised inflammatory markers, although most of this evidence is associative rather than prospectively predictive. The distinction between markers of current burden, markers of prognosis, and markers of treatment response is emphasised. Composite models integrating clinical characteristics, patient-reported outcomes, and biomarkers represent a promising approach toward precision management of CSU, although no validated prognostic tool is currently available for routine clinical use.
SN - 2673-6101
ER -